Peringatan Keamanan

Signs and symptoms vary in severity depending upon factors such as the amount of drug absorbed, the age of the patient, and the time elapsed since drug ingestion. Critical manifestations of overdose include cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic toxicity. In U.S. clinical trials, 2 deaths occurred in 12 reported cases of acute overdosage with Anafranil either alone or in combination with other drugs. One death involved a patient suspected of ingesting a dose of 7000 mg. The second death involved a patient suspected of ingesting a dose of 5750 mg.
Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression.
Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.

Clomipramine

DB01242

small molecule approved investigational vet_approved

Deskripsi

Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine.

Struktur Molekul 2D

Berat 314.852
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).
Volume Distribusi ~ 17 L/kg (range: 9-25 L/kg). Clomipramine is capable of distributing into the cerebrospinal fluid, the brain, and into breast milk.
Klirens (Clearance) -

Absorpsi

Well absorbed from the GI tract following oral administration. Bioavailability is approximately 50% orally due to extensive first-pass metabolism. Bioavailability is not affected by food. Peak plasma concentrations occurred 2-6 hours following oral administration of a single 50 mg dose. The peak plasma concentration ranged from 56 ng/mL to 154 mg/mL (mean, 92 ng/mL). There are large interindividual variations in plasma concentrations occur, partly due to genetic differences in clomipramine metabolism. On average, steady state plasma concentrations are achieved in 1-2 weeks following multiple dose oral administration. Smoking appears to lower the steady-state plasma concentration of clomipramine, but not its active metabolite desmethylclomipramine.

Metabolisme

Extensively metabolized in the liver. The main active metabolite is desmethylclomipramine, which is formed by N-demethylation of clomipramine via CYP2C19, 3A4 and 1A2. Other metabolites and their glucuronide conjugates are also produced. Other metabolites of clomipramine include 8-hydroxyclomipramine formed via 8-hydroxylation, 2-hydroxyclomipramine formed via 2-hydroxylation, and clomipramine N-oxide formed by N-oxidation. Desmethylclomipramine is further metabolized to 8-hydroxydesmethylclomipramine and didesmethylclomipramine, which are formed by 8-hydroxylation and N-demethylation, respectively. 8-Hydroxyclomipramine and 8-hydroxydesmethylclomipramine are pharmacologically active; however, their clinical relevance remains unknown.

Rute Eliminasi

Urine (51-60%) and feces via biliary elimination (24-32%)

Farmakogenomik

9 Varian
CYP2D6 (rs3892097)

Patients with this genotype have reduced metabolism of clomipramine.

CYP2D6 (rs35742686)

The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.

CYP2D6 (rs3892097)

The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.

CYP2D6 (None)

The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.

CYP2D6 (rs5030655)

The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.

CYP2C19 (rs4244285)

The presence of this polymorphism in CYP2C19 is associated with poor metabolism of clomipramine.

CYP2C19 (rs4986893)

The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of clomipramine.

CYP2D6 (rs1135824)

The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.

CYP2D6 (rs28371733)

The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.

Interaksi Makanan

3 Data
  • 1. Avoid alcohol.
  • 2. Avoid grapefruit products.
  • 3. Take with food. Food reduces irritation.

Interaksi Obat

2343 Data
Ivabradine Ivabradine may increase the QTc-prolonging activities of Clomipramine.
Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Clomipramine is combined with Duloxetine.
Levodopa The risk or severity of hypotension and orthostatic hypotension can be increased when Clomipramine is combined with Levodopa.
Risperidone Clomipramine may increase the hypotensive activities of Risperidone.
Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Clomipramine.
Citalopram The serum concentration of Citalopram can be increased when it is combined with Clomipramine.
Deferasirox The serum concentration of Clomipramine can be increased when it is combined with Deferasirox.
Flibanserin The serum concentration of Flibanserin can be increased when it is combined with Clomipramine.
Peginterferon alfa-2b The serum concentration of Clomipramine can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Clomipramine can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Clomipramine can be decreased when it is combined with Teriflunomide.
Valsartan Clomipramine may decrease the antihypertensive activities of Valsartan.
Ramipril Clomipramine may decrease the antihypertensive activities of Ramipril.
Remikiren Clomipramine may decrease the antihypertensive activities of Remikiren.
Guanadrel Clomipramine may decrease the antihypertensive activities of Guanadrel.
Olmesartan Clomipramine may decrease the antihypertensive activities of Olmesartan.
Minoxidil Clomipramine may decrease the antihypertensive activities of Minoxidil.
Trandolapril Clomipramine may decrease the antihypertensive activities of Trandolapril.
Benazepril Clomipramine may decrease the antihypertensive activities of Benazepril.
Candoxatril Clomipramine may decrease the antihypertensive activities of Candoxatril.
Nitroglycerin Clomipramine may decrease the antihypertensive activities of Nitroglycerin.
Cryptenamine Clomipramine may decrease the antihypertensive activities of Cryptenamine.
Candesartan cilexetil Clomipramine may decrease the antihypertensive activities of Candesartan cilexetil.
Tolazoline Clomipramine may decrease the antihypertensive activities of Tolazoline.
Eprosartan Clomipramine may decrease the antihypertensive activities of Eprosartan.
Quinapril Clomipramine may decrease the antihypertensive activities of Quinapril.
Omapatrilat Clomipramine may decrease the antihypertensive activities of Omapatrilat.
Phenoxybenzamine Clomipramine may decrease the antihypertensive activities of Phenoxybenzamine.
Deserpidine Clomipramine may decrease the antihypertensive activities of Deserpidine.
Terazosin Clomipramine may decrease the antihypertensive activities of Terazosin.
Rescinnamine Clomipramine may decrease the antihypertensive activities of Rescinnamine.
Cilazapril Clomipramine may decrease the antihypertensive activities of Cilazapril.
Saprisartan Clomipramine may decrease the antihypertensive activities of Saprisartan.
Spirapril Clomipramine may decrease the antihypertensive activities of Spirapril.
Dexpropranolol Clomipramine may decrease the antihypertensive activities of Dexpropranolol.
Diethylnorspermine Clomipramine may decrease the antihypertensive activities of Diethylnorspermine.
Temocapril Clomipramine may decrease the antihypertensive activities of Temocapril.
Indoramin Clomipramine may decrease the antihypertensive activities of Indoramin.
Trimazosin Clomipramine may decrease the antihypertensive activities of Trimazosin.
Rauwolfia serpentina root Clomipramine may decrease the antihypertensive activities of Rauwolfia serpentina root.
Angiotensin 1-7 Clomipramine may decrease the antihypertensive activities of Angiotensin 1-7.
Imidapril Clomipramine may decrease the antihypertensive activities of Imidapril.
BQ-123 Clomipramine may decrease the antihypertensive activities of BQ-123.
Zofenopril Clomipramine may decrease the antihypertensive activities of Zofenopril.
Guanoxan Clomipramine may decrease the antihypertensive activities of Guanoxan.
Delapril Clomipramine may decrease the antihypertensive activities of Delapril.
Vincamine Clomipramine may decrease the antihypertensive activities of Vincamine.
Linsidomine Clomipramine may decrease the antihypertensive activities of Linsidomine.
Guanoxabenz Clomipramine may decrease the antihypertensive activities of Guanoxabenz.
Tolonidine Clomipramine may decrease the antihypertensive activities of Tolonidine.
Endralazine Clomipramine may decrease the antihypertensive activities of Endralazine.
Cadralazine Clomipramine may decrease the antihypertensive activities of Cadralazine.
Bietaserpine Clomipramine may decrease the antihypertensive activities of Bietaserpine.
Guanazodine Clomipramine may decrease the antihypertensive activities of Guanazodine.
Methoserpidine Clomipramine may decrease the antihypertensive activities of Methoserpidine.
Guanoclor Clomipramine may decrease the antihypertensive activities of Guanoclor.
Candesartan Clomipramine may decrease the antihypertensive activities of Candesartan.
Tocopherylquinone Clomipramine may decrease the antihypertensive activities of Tocopherylquinone.
Benazeprilat Clomipramine may decrease the antihypertensive activities of Benazeprilat.
Fosinoprilat Clomipramine may decrease the antihypertensive activities of Fosinoprilat.
Ramiprilat Clomipramine may decrease the antihypertensive activities of Ramiprilat.
Perindoprilat Clomipramine may decrease the antihypertensive activities of Perindoprilat.
Quinaprilat Clomipramine may decrease the antihypertensive activities of Quinaprilat.
Enalapril Clomipramine may decrease the antihypertensive activities of Enalapril.
Captopril Clomipramine may decrease the antihypertensive activities of Captopril.
Pinacidil Clomipramine may decrease the antihypertensive activities of Pinacidil.
Riociguat Clomipramine may decrease the antihypertensive activities of Riociguat.
Aliskiren Clomipramine may decrease the antihypertensive activities of Aliskiren.
Naftopidil Clomipramine may decrease the antihypertensive activities of Naftopidil.
Dexniguldipine Clomipramine may decrease the antihypertensive activities of Dexniguldipine.
Prazosin Clomipramine may decrease the antihypertensive activities of Prazosin.
Ambrisentan Clomipramine may decrease the antihypertensive activities of Ambrisentan.
Selexipag Clomipramine may decrease the antihypertensive activities of Selexipag.
Nitroprusside Clomipramine may decrease the antihypertensive activities of Nitroprusside.
Amlodipine The metabolism of Clomipramine can be decreased when combined with Amlodipine.
Nisoldipine Clomipramine may decrease the antihypertensive activities of Nisoldipine.
Fosinopril Clomipramine may decrease the antihypertensive activities of Fosinopril.
Bisoprolol Clomipramine may decrease the antihypertensive activities of Bisoprolol.
Phentolamine Clomipramine may decrease the antihypertensive activities of Phentolamine.
Lisinopril Clomipramine may decrease the antihypertensive activities of Lisinopril.
Perindopril Clomipramine may decrease the antihypertensive activities of Perindopril.
Fenoldopam Clomipramine may decrease the antihypertensive activities of Fenoldopam.
Tadalafil Clomipramine may decrease the antihypertensive activities of Tadalafil.
Guanethidine Clomipramine may decrease the antihypertensive activities of Guanethidine.
Epoprostenol Clomipramine may decrease the antihypertensive activities of Epoprostenol.
Macitentan Clomipramine may decrease the antihypertensive activities of Macitentan.
Enalaprilat Clomipramine may decrease the antihypertensive activities of Enalaprilat.
Levamlodipine Clomipramine may decrease the antihypertensive activities of Levamlodipine.
Lercanidipine Clomipramine may decrease the antihypertensive activities of Lercanidipine.
Diazoxide Clomipramine may decrease the antihypertensive activities of Diazoxide.
Buprenorphine Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
Hydrocodone Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Magnesium sulfate The therapeutic efficacy of Clomipramine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Clomipramine may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.

Target Protein

Sodium-dependent serotonin transporter SLC6A4
5-hydroxytryptamine receptor 2A HTR2A
5-hydroxytryptamine receptor 2B HTR2B
5-hydroxytryptamine receptor 2C HTR2C
Sodium-dependent noradrenaline transporter SLC6A2
Glutathione S-transferase P GSTP1

Referensi & Sumber

Synthesis reference: Schindler, W. and Dietrich, H.; US. Patent 3,515,785; June 2,1970; assigned to Geigy Chemical Corp.

Contoh Produk & Brand

Produk: 140 • International brands: 2
Produk
  • Act Clomipramine
    Tablet • 10 mg • Oral • Canada • Approved
  • Act Clomipramine
    Tablet • 25 mg • Oral • Canada • Approved
  • Act Clomipramine
    Tablet • 50 mg • Oral • Canada • Approved
  • Altius-clomipramine
    Tablet • 10 mg • Oral • Canada • Generic • Approved
  • Altius-clomipramine
    Tablet • 25 mg • Oral • Canada • Generic • Approved
  • Altius-clomipramine
    Tablet • 50 mg • Oral • Canada • Generic • Approved
  • Anafranil
    Capsule • 25 mg/1 • Oral • US • Approved
  • Anafranil
    Capsule • 50 mg/1 • Oral • US • Approved
Menampilkan 8 dari 140 produk.
International Brands
  • Anapramine
  • Hydiphen — Arzneimittelwerk Dresden

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul